NAMS Menopause Certification Practice Exam 2026 | Complete Questions,
Verified Answers & Detailed Rationales | Comprehensive Exam Review Pack
This comprehensive exam review pack is designed to help healthcare
professionals master the essential concepts tested on the NAMS Menopause
Certification examination. It features original practice questions, accurate
answers, and detailed rationales that reinforce clinical reasoning and support
effective exam preparation
1. A 51-year-old woman with an intact uterus presents with
moderate vasomotor symptoms. She requests hormone therapy.
Which component must be included in her regimen to prevent
endometrial hyperplasia?
A) Low-dose testosterone
B) Selective estrogen receptor modulators alone
C) A progestogen combined with estrogen
D) Vaginal dehydroepiandrosterone (DHEA)
Rationale: Systemic estrogen therapy stimulates the endometrium. In patients with an
intact uterus, a progestogen must always be added to counter this effect and eliminate
the increased risk of endometrial hyperplasia and carcinoma.
2. A 55-year-old postmenopausal patient undergoes a dual-
energy X-ray absorptiometry (DXA) scan. The report indicates a
T-score of -2.7 at the lumbar spine. What is the correct diagnostic
classification for this patient?
A) Osteopenia
B) Normal bone density
C) Osteoporosis
D) Severe osteoporosis with fracture risk
Rationale: According to the World Health Organization classification criteria,
osteoporosis is formally diagnosed when a bone mineral density T-score is -2.5 or lower
(≤ -2.5) at the spine, femoral neck, or total hip.
3. A patient is seeking nonpharmacologic treatment options for
severe night sweats. She prefers options backed by strong
clinical evidence in the Menopause Society guidelines. Which
pair of interventions should be recommended?
,A) Paced respiration and yoga
B) Cognitive behavioral therapy and clinical hypnosis
C) Acupuncture and reflexology
D) Herbal supplements and magnetic therapy
Rationale: Cognitive behavioral therapy (CBT) and clinical hypnosis are the only
nonpharmacologic behavioral interventions strongly recommended by guidelines due to
robust data demonstrating significant reduction in vasomotor symptom interference.
4. Which of the following describes a key pharmacological
advantage of prescribing transdermal estradiol over oral
estrogen therapy?
A) Increased first-pass hepatic clearance
B) Lower risk of venous thromboembolism (VTE)
C) Significant elevation of serum triglycerides
D) Higher production of sex hormone-binding globulin
Rationale: Transdermal estradiol absorption bypasses the liver's first-pass metabolism.
This avoids the upregulation of coagulation factors and delivers a significantly lower risk
of venous thromboembolism and stroke compared to oral options.
5. A 59-year-old patient transitioned through menopause 7 years
ago. She complains of worsening vaginal dryness, irritation, and
dyspareunia. According to the STRAW + 10 criteria, which
clinical stage is she in?
A) Stage +1a
B) Stage +1c
C) Stage +2
D) Stage -2
Rationale: Stage +2 represents late postmenopause, beginning approximately 5 to 8
years after the final menstrual period. In this phase, symptoms of the genitourinary
syndrome of menopause (GSM) and somatic aging typically become more pronounced.
6. A 47-year-old woman presents with irregular menstrual cycles,
where her cycle length varies by 9 days compared to her
baseline. She also describes occasional mild hot flushes. Under
the STRAW + 10 staging system, what is her classification?
A) Stage -3 (reproductive)
B) Stage -2 (early menopausal transition)
C) Stage -1 (late menopausal transition)
D) Stage +1a (early postmenopause)
,Rationale: The early menopausal transition (Stage -2) is characterized by a persistent
alteration in menstrual cycle length, specifically a variable cycle duration that differs by 7
or more days from the patient's normal baseline.
7. A 49-year-old patient reports amenorrhea lasting 3 consecutive
months, accompanied by worsening sleep disturbances and
frequent hot flushes. What STRAW + 10 stage does this
presentation reflect?
A) Stage -2 (early menopausal transition)
B) Stage -1 (late menopausal transition)
C) Stage +1a (early postmenopause)
D) Stage +1b (early postmenopause)
Rationale: The late menopausal transition (Stage -1) is clinically defined by the
occurrence of skipped cycles leading to a prolonged period of amenorrhea lasting 60
days or longer, often accompanied by intensified vasomotor symptoms.
8. At what specific age do current clinical guidelines recommend
initiating routine bone mineral density (BMD) screening via DXA
in postmenopausal women without additional risk factors?
A) 50 years of age
B) 55 years of age
C) 60 years of age
D) 65 years of age
Rationale: Routine bone mineral density testing via DXA screening is recommended to
begin at age 65 for all postmenopausal women who do not possess independent high-
risk factors for accelerated bone loss or osteoporotic fractures.
9. A 52-year-old postmenopausal woman has an intact uterus and
requires systemic hormone therapy. Which progestogen choice
is widely preferred to minimize adverse effects on breast tissue
and lipid profiles?
A) Medroxyprogesterone acetate
B) Norethindrone acetate
C) Norgestrel
D) Oral micronized progesterone
Rationale: Oral micronized progesterone is highly preferred because it possesses a
more favorable metabolic profile, does not adversely alter lipids, and carries a lower risk
of breast cancer activation compared to synthetic progestins.
10. A 54-year-old patient presents with severe vaginal burning
and pain during intercourse. She has no vasomotor symptoms
, and does not want systemic therapy. What is the most
appropriate first-line medical intervention?
A) Oral conjugated equine estrogens
B) Transdermal estradiol patch
C) Low-dose vaginal estrogen cream
D) Oral bazedoxifene
Rationale: For isolated symptoms of vulvovaginal atrophy or genitourinary syndrome of
menopause (GSM), low-dose local vaginal estrogen is the preferred first-line therapy
due to minimal systemic absorption and high local efficacy.
11. Which of the following represents an absolute
contraindication to the initiation of systemic hormone therapy for
menopausal symptoms?
A) Well-controlled primary hypertension
B) Hypercholesterolemia
C) Unexplained abnormal uterine bleeding
D) Controlled type 2 diabetes mellitus
Rationale: Unexplained or undiagnosed abnormal uterine bleeding is a strict absolute
contraindication to hormone therapy. The underlying cause, such as endometrial
hyperplasia or malignancy, must be fully investigated and ruled out first.
12. A 42-year-old woman experiences spontaneous cessation of
menses accompanied by elevated follicle-stimulating hormone
(FSH) levels measured on two separate occasions. What is her
diagnosis?
A) Normal menopausal transition
B) Premature ovarian insufficiency (POI)
C) Early menopause
D) Stage -1 late transition
Rationale: Premature ovarian insufficiency (POI) is defined as the loss of ovarian
function prior to the age of 40, though clinically presenting similarly to early menopause
(ages 40-45), and requires confirmation via elevated FSH levels.
13. For a patient diagnosed with premature ovarian insufficiency
(POI) or early menopause, how long is it generally recommended
to continue hormone replacement therapy?
A) For a maximum of 3 years
B) Until age 45
C) Until at least the median age of natural menopause (approx. age 51)
D) Indefinitely, without an upper age limit
Verified Answers & Detailed Rationales | Comprehensive Exam Review Pack
This comprehensive exam review pack is designed to help healthcare
professionals master the essential concepts tested on the NAMS Menopause
Certification examination. It features original practice questions, accurate
answers, and detailed rationales that reinforce clinical reasoning and support
effective exam preparation
1. A 51-year-old woman with an intact uterus presents with
moderate vasomotor symptoms. She requests hormone therapy.
Which component must be included in her regimen to prevent
endometrial hyperplasia?
A) Low-dose testosterone
B) Selective estrogen receptor modulators alone
C) A progestogen combined with estrogen
D) Vaginal dehydroepiandrosterone (DHEA)
Rationale: Systemic estrogen therapy stimulates the endometrium. In patients with an
intact uterus, a progestogen must always be added to counter this effect and eliminate
the increased risk of endometrial hyperplasia and carcinoma.
2. A 55-year-old postmenopausal patient undergoes a dual-
energy X-ray absorptiometry (DXA) scan. The report indicates a
T-score of -2.7 at the lumbar spine. What is the correct diagnostic
classification for this patient?
A) Osteopenia
B) Normal bone density
C) Osteoporosis
D) Severe osteoporosis with fracture risk
Rationale: According to the World Health Organization classification criteria,
osteoporosis is formally diagnosed when a bone mineral density T-score is -2.5 or lower
(≤ -2.5) at the spine, femoral neck, or total hip.
3. A patient is seeking nonpharmacologic treatment options for
severe night sweats. She prefers options backed by strong
clinical evidence in the Menopause Society guidelines. Which
pair of interventions should be recommended?
,A) Paced respiration and yoga
B) Cognitive behavioral therapy and clinical hypnosis
C) Acupuncture and reflexology
D) Herbal supplements and magnetic therapy
Rationale: Cognitive behavioral therapy (CBT) and clinical hypnosis are the only
nonpharmacologic behavioral interventions strongly recommended by guidelines due to
robust data demonstrating significant reduction in vasomotor symptom interference.
4. Which of the following describes a key pharmacological
advantage of prescribing transdermal estradiol over oral
estrogen therapy?
A) Increased first-pass hepatic clearance
B) Lower risk of venous thromboembolism (VTE)
C) Significant elevation of serum triglycerides
D) Higher production of sex hormone-binding globulin
Rationale: Transdermal estradiol absorption bypasses the liver's first-pass metabolism.
This avoids the upregulation of coagulation factors and delivers a significantly lower risk
of venous thromboembolism and stroke compared to oral options.
5. A 59-year-old patient transitioned through menopause 7 years
ago. She complains of worsening vaginal dryness, irritation, and
dyspareunia. According to the STRAW + 10 criteria, which
clinical stage is she in?
A) Stage +1a
B) Stage +1c
C) Stage +2
D) Stage -2
Rationale: Stage +2 represents late postmenopause, beginning approximately 5 to 8
years after the final menstrual period. In this phase, symptoms of the genitourinary
syndrome of menopause (GSM) and somatic aging typically become more pronounced.
6. A 47-year-old woman presents with irregular menstrual cycles,
where her cycle length varies by 9 days compared to her
baseline. She also describes occasional mild hot flushes. Under
the STRAW + 10 staging system, what is her classification?
A) Stage -3 (reproductive)
B) Stage -2 (early menopausal transition)
C) Stage -1 (late menopausal transition)
D) Stage +1a (early postmenopause)
,Rationale: The early menopausal transition (Stage -2) is characterized by a persistent
alteration in menstrual cycle length, specifically a variable cycle duration that differs by 7
or more days from the patient's normal baseline.
7. A 49-year-old patient reports amenorrhea lasting 3 consecutive
months, accompanied by worsening sleep disturbances and
frequent hot flushes. What STRAW + 10 stage does this
presentation reflect?
A) Stage -2 (early menopausal transition)
B) Stage -1 (late menopausal transition)
C) Stage +1a (early postmenopause)
D) Stage +1b (early postmenopause)
Rationale: The late menopausal transition (Stage -1) is clinically defined by the
occurrence of skipped cycles leading to a prolonged period of amenorrhea lasting 60
days or longer, often accompanied by intensified vasomotor symptoms.
8. At what specific age do current clinical guidelines recommend
initiating routine bone mineral density (BMD) screening via DXA
in postmenopausal women without additional risk factors?
A) 50 years of age
B) 55 years of age
C) 60 years of age
D) 65 years of age
Rationale: Routine bone mineral density testing via DXA screening is recommended to
begin at age 65 for all postmenopausal women who do not possess independent high-
risk factors for accelerated bone loss or osteoporotic fractures.
9. A 52-year-old postmenopausal woman has an intact uterus and
requires systemic hormone therapy. Which progestogen choice
is widely preferred to minimize adverse effects on breast tissue
and lipid profiles?
A) Medroxyprogesterone acetate
B) Norethindrone acetate
C) Norgestrel
D) Oral micronized progesterone
Rationale: Oral micronized progesterone is highly preferred because it possesses a
more favorable metabolic profile, does not adversely alter lipids, and carries a lower risk
of breast cancer activation compared to synthetic progestins.
10. A 54-year-old patient presents with severe vaginal burning
and pain during intercourse. She has no vasomotor symptoms
, and does not want systemic therapy. What is the most
appropriate first-line medical intervention?
A) Oral conjugated equine estrogens
B) Transdermal estradiol patch
C) Low-dose vaginal estrogen cream
D) Oral bazedoxifene
Rationale: For isolated symptoms of vulvovaginal atrophy or genitourinary syndrome of
menopause (GSM), low-dose local vaginal estrogen is the preferred first-line therapy
due to minimal systemic absorption and high local efficacy.
11. Which of the following represents an absolute
contraindication to the initiation of systemic hormone therapy for
menopausal symptoms?
A) Well-controlled primary hypertension
B) Hypercholesterolemia
C) Unexplained abnormal uterine bleeding
D) Controlled type 2 diabetes mellitus
Rationale: Unexplained or undiagnosed abnormal uterine bleeding is a strict absolute
contraindication to hormone therapy. The underlying cause, such as endometrial
hyperplasia or malignancy, must be fully investigated and ruled out first.
12. A 42-year-old woman experiences spontaneous cessation of
menses accompanied by elevated follicle-stimulating hormone
(FSH) levels measured on two separate occasions. What is her
diagnosis?
A) Normal menopausal transition
B) Premature ovarian insufficiency (POI)
C) Early menopause
D) Stage -1 late transition
Rationale: Premature ovarian insufficiency (POI) is defined as the loss of ovarian
function prior to the age of 40, though clinically presenting similarly to early menopause
(ages 40-45), and requires confirmation via elevated FSH levels.
13. For a patient diagnosed with premature ovarian insufficiency
(POI) or early menopause, how long is it generally recommended
to continue hormone replacement therapy?
A) For a maximum of 3 years
B) Until age 45
C) Until at least the median age of natural menopause (approx. age 51)
D) Indefinitely, without an upper age limit
